As part of its strategic vision, the Vall d’Hebron Institute of Oncology (VHIO) is actively involved in a wide range of European Union (EU)-funded initiatives designed to advance cancer research and care. By leading and participating in competitive research projects, international consortiums, and policy-driven Joint Actions, VHIO helps shape a more integrated and collaborative European cancer research– and care ecosystem.
Understanding the EU Project Landscape
The European Union (EU) is strongly committed to tackling cancer, channeling significant resources into research, prevention, treatment, and care. Its overarching goal is to reduce the burden of cancer and improve outcomes for all citizens across Europe. To achieve this, the EU focuses on several key priorities: cancer prevention, early detection and diagnosis, equal access to high-quality care, and improving the quality of life for cancer patients and survivors.
This commitment is reflected in flagship initiatives such as the EU Mission on Cancer (Horizon Europe), and the EU4Health Programme (Europe´s Beating Cancer Plan). These programs support a broad spectrum of activities—from fundamental research to clinical trials and guidelines of implementation—aimed at transforming cancer care and strengthening Europe as a whole.
EU Projects vs. Joint Actions: What’s the Difference?
“Although often interconnected, Joint Actions and EU Projects serve different purposes within the European Union’s funding and policy landscape,” explains Christina Stangl, Scientific Manager for EU Joint Actions at VHIO.
Both are supported by EU funds, but differ in research focus, structure, selection, and objectives:
- EU Projects (e.g., under Horizon Europe or Erasmus+) are competitive and awarded through open calls. Their focus is typically on research, innovation, and capacity building.
- Joint Actions, primarily funded through EU4Health, are non-competitive and involve national authorities or nominated institutions (competent authorities). Joint Actions aim to promote best practices and guidelines and implement policies across EU Member States.
Selection Process
EU Projects undergo rigorous evaluation based on excellence, impact, and feasibility. Joint Actions, by contrast, are reserved for designated institutions and are not subject to open calls.
Goals and Outcomes
While EU Projects often pursue scientific discoveries and clinical innovation, Joint Actions support the harmonization of public health strategies and collaborative implementation among and across countries.
“For example, VHIO leads CCE_DART, a Horizon Europe-funded EU Project that develops innovative designs for clinical oncology trials. In contrast, Joint Actions might focus on aligning policy implementation across the EU,” Christina adds.
VHIO’s Contribution: Leadership, Expertise, and Impact
Actively participating in European research and policy networks is central to VHIO’s mission to accelerate advances in oncology.
“We believe that cross-border collaboration is key to transforming care and advancing outcomes,” says Alejandro Piris, Chief Scientific Officer at VHIO.
This belief is reflected in VHIO’s leadership across several major EU-funded initiatives. The institute served as member of the UNCAN.eu Coordination and Support Action, a key program of the EU Cancer Mission.[/vc_column_text]
Since 2023, VHIO has also led Cancer Core Europe, a strategic alliance of leading cancer centers dedicated to accelerating translational research and sharing best practices across borders.
Elena Chavarria, Scientific Manager for EU Consortia, comments “These collaborations not only accelerate scientific discovery but also help ensure that research is translated into tangible, timely benefits for patients throughout Europe”.
Looking Ahead
VHIO remains determined in its commitment to shaping the future of cancer research and treatment in Europe. By championing collaborative projects and policy efforts, we aim to deliver real-world benefits for people affected by cancer—across Europe and beyond.
